Video

Emerging therapies in AMD management

Author(s):

OT Staff Reports

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Anat Loewenstein, MD, chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

See more AMD Awareness content here, here, and here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
Related Content
Handheld fundus camera from Optomed USA launched for use in any care setting
August 1st 2025

Handheld fundus camera from Optomed USA launched for use in any care setting

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
August 1st 2025

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Opus Genetics partners with Global RDH12 Alliance
August 1st 2025

Opus Genetics partners with Global RDH12 Alliance

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
August 1st 2025

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

Logos for Topcon Healthcare (left, black and purple) and Intelligent Retinal Imaging Systems (IRIS, right, blue and green). Concept image for diabetic eye disease retina screening company merger. Image courtesy of Topcon Healthcare.
August 1st 2025

Topcon acquires Intelligent Retinal Imaging Systems, bolstering AI-powered screenings

Retinal microvasculature on OCTA may predict coronary artery disease risk
August 1st 2025

Retinal microvasculature on OCTA may predict coronary artery disease risk

© 2025 MJH Life Sciences

All rights reserved.